Related references
Note: Only part of the references are listed.Preparation and in vitro characterization of histidine trimethyl chitosan conjugated nanocomplex incorporated into injectable thermosensitive hydrogels for localized gene delivery
Vajihe Akbari et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2022)
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Eryn Blass et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis
Zicong You et al.
CANCER CELL INTERNATIONAL (2021)
Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.
Ignacio Ortego et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2+GMCSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer.
Snehal Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+advanced stage breast cancer.
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
David A. Bernal-Estevez et al.
FRONTIERS IN IMMUNOLOGY (2021)
Lipid nanoparticles for mRNA delivery
Xucheng Hou et al.
NATURE REVIEWS MATERIALS (2021)
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
Robert H. Vonderheide et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines
Jose Alexandre Ferreira et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2021)
A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications
Furong Qin et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
Pierre Rosenbaum et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Peptide-Based Vaccines: Current Progress and Future Challenges
Ryan J. Malonis et al.
CHEMICAL REVIEWS (2020)
Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
G. Travis Clifton et al.
CLINICAL CANCER RESEARCH (2020)
Comparison of DND and mRNA vaccines against cancer
Zohreh Jahanafrooz et al.
DRUG DISCOVERY TODAY (2020)
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Abishek Wadhwa et al.
PHARMACEUTICS (2020)
Ex vivo pulsed dendritic cell vaccination against cancer
Yang-zhuo Gu et al.
ACTA PHARMACOLOGICA SINICA (2020)
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
Tommy A. Brown et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion
Ellyn Hughes et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
Anna Lucia Tornesello et al.
CANCERS (2020)
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
Maria Julia Lamberti et al.
PHARMACEUTICS (2020)
Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer
Uhi Toh et al.
CANCER SCIENCE (2020)
Addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients
A. Urrizola et al.
ANNALS OF ONCOLOGY (2020)
T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
M. Schmidt et al.
ANNALS OF ONCOLOGY (2020)
Cancer immunotherapy via targeted TGF-β signalling blockade in THcells
Shun Li et al.
NATURE (2020)
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
Anusha Kalbasi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
Yuki Tanaka et al.
SCIENTIFIC REPORTS (2020)
Selecting Target Antigens for Cancer Vaccine Development
Luigi Buonaguro et al.
VACCINES (2020)
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
Vajihe Akbari et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform
Celia Jacoberger-Foissac et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
Hoyoung M. Maeng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer
Jian Gao et al.
JOURNAL OF BREAST CANCER (2019)
Fates of CD8+ T cells in Tumor Microenvironment
Nomathamsanqa Resegofetse Maimela et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice
Atefeh Arab et al.
JOURNAL OF DRUG TARGETING (2018)
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39′: An analysis of safety and immune response
Timothy J. Vreeland et al.
CLINICAL IMMUNOLOGY (2018)
Dendritic Cell-Based Cancer Vaccines
Patricia M. Santos et al.
JOURNAL OF IMMUNOLOGY (2018)
Molecular Subtypes and Local-Regional Control of Breast Cancer
Simona Maria Fragomeni et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2018)
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
Hatem Soliman et al.
Oncotarget (2018)
Peptide-Based Immunotherapeutics and Vaccines 2017
Pedro Reche et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Metastatic and triple-negative breast cancer: challenges and treatment options
Sumayah Al-Mahmood et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer
Lijuan Wei et al.
FRONTIERS IN IMMUNOLOGY (2018)
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors
Chang-Long Chen et al.
ONCOIMMUNOLOGY (2018)
First-in-man study of Ad-sig-hMUC1/ecdCD40L vaccine for immunotherapy of MUC1 overexpressing epithelial cancers.
Tira Jing Ying Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
DNA VaccinesHow Far From Clinical Use?
Dominika Hobernik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
Mandy van Gulijk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Yixiao Feng et al.
GENES & DISEASES (2018)
Breast cancer vaccination comes to age: impacts of bioinformatics
Sepideh Parvizpour et al.
BIOIMPACTS (2018)
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Lea Lowenfeld et al.
CLINICAL CANCER RESEARCH (2017)
Triple-negative breast cancer: is there a treatment on the horizon?
Hui Yao et al.
ONCOTARGET (2017)
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer
Lea Lowenfeld et al.
ONCOIMMUNOLOGY (2017)
Immunotherapy for the treatment of breast cancer
Mariela A. Moreno Ayala et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Progress in nonviral gene therapy for breast cancer and what comes next?
Giulia Bottai et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Cytosolic nucleic acid sensors and innate immune regulation
Daisuke Ori et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
Advances in systemic therapy for metastatic breast cancer: future perspectives
S. P. Corona et al.
MEDICAL ONCOLOGY (2017)
Breast cancer statistics, 2017, racial disparity in mortality by state
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients
G. Travis Clifton et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Xiaoxian Li et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines
Katherine Sanchez et al.
CURRENT PROBLEMS IN CANCER (2016)
Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles
Eleni Maria Varypataki et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
Elizabeth A. Mittendorf et al.
ONCOTARGET (2016)
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Mohammad A. Jafri et al.
GENOME MEDICINE (2016)
Dendritic cell vaccines: A review of recent developments and their potential pediatric application
Jennifer D. Elster et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses
Viswa Teja Colluru et al.
ONCOIMMUNOLOGY (2016)
Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells
Wenjie Yin et al.
EBIOMEDICINE (2016)
Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Spectrum of Genetic Mutations in Breast Cancer
Asfandyar Sheikh et al.
Asian Pacific Journal of Cancer Prevention (2015)
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Adjuvant HER2/neu peptide cancer vaccines in breast cancer
Guy T. Clifton et al.
IMMUNOTHERAPY (2015)
Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli
Vajihe Akbari et al.
PROTEIN EXPRESSION AND PURIFICATION (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
Shujing Wang et al.
PROTEIN & CELL (2015)
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer A Randomized Clinical Trial
Christopher R. Heery et al.
JAMA ONCOLOGY (2015)
Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide
Duane A. Mitchell et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.
William Rayford Gwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes
S. D. Soysal et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist
Abu-Baker M. Abdel-Aal et al.
CHEMBIOCHEM (2014)
Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
Venkataswarup Tiriveedhi et al.
CLINICAL CANCER RESEARCH (2014)
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
Erika J. Schneble et al.
IMMUNOTHERAPY (2014)
Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli
Vajihe Akbari et al.
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY (2014)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
Hisae Iinuma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer
Manijeh Mahdavi et al.
TUMOR BIOLOGY (2014)
Antigen-specific vaccines for cancer treatment
Maria Tagliamonte et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells
Venkataswarup Tiriveedhi et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity
Tae Heung Kang et al.
CANCER RESEARCH (2013)
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences
Jun Ren et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2013)
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1
Stamatis Vassilaros et al.
IMMUNOTHERAPY (2013)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways
James C. M. Wang et al.
VIROLOGY JOURNAL (2013)
Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial
Nuhad K. Ibrahim et al.
JOURNAL OF CANCER (2013)
Dendritic Cells in the Cancer Microenvironment
Yang Ma et al.
JOURNAL OF CANCER (2013)
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
Jian Yan et al.
CANCER IMMUNOLOGY RESEARCH (2013)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T Cells
John J. Engelhardt et al.
CANCER CELL (2012)
Current management and treatment strategies for breast cancer
John H. Howard et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2012)
Dendritic cell-based vaccines: barriers and opportunities
Jessica A. Cintolo et al.
FUTURE ONCOLOGY (2012)
A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
Gary K. Koski et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Developing mRNA-vaccine technologies
Thomas Schlake et al.
RNA BIOLOGY (2012)
Harnessing DNA-induced immune responses for improving cancer vaccines
Andres A. Herrada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
Damya Laoui et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
Soyoung Baek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
Qing Yi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Results of the First Phase 1 Clinical Trial of the HER-2/neu Peptide (GP2) Vaccine in Disease-Free Breast Cancer Patients
Mark G. Carmichael et al.
CANCER (2010)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients
Esther M. de Kruijf et al.
JOURNAL OF IMMUNOLOGY (2010)
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells
S. Bafna et al.
ONCOGENE (2010)
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
Jeremy D. Gates et al.
VACCINE (2010)
Therapeutic Breast Cancer Vaccines A New Strategy for Early-Stage Disease
Nathan M. Shumway et al.
BIODRUGS (2009)
Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase I
Qiuyan Liu et al.
JOURNAL OF IMMUNOLOGY (2009)
Use of tumour-responsive T cells as cancer treatment
Mary L. Disis et al.
LANCET (2009)
Lentiviral Vectors Transduce Proliferating Dendritic Cell Precursors Leading to Persistent Antigen Presentation and Immunization
Frederick Arce et al.
MOLECULAR THERAPY (2009)
Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice
S. Sas et al.
CANCER GENE THERAPY (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
The use of dendritic cells in cancer immunotherapy
Alessio Nencioni et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma
Miguel-Angel Perales et al.
MOLECULAR THERAPY (2008)
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy
Evelien L. J. M. Smits et al.
ONCOLOGIST (2008)
Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17
Salome LeibundGut-Landmann et al.
NATURE IMMUNOLOGY (2007)
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
Brian J. Czerniecki et al.
CANCER RESEARCH (2007)
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
Vasso Apostolopoulos et al.
BREAST CANCER RESEARCH (2006)
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
GE Peoples et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction
N Okada et al.
GENE THERAPY (2005)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
D Avigan et al.
CLINICAL CANCER RESEARCH (2004)
Dendritic cells are dysfunctional in patients with operable breast cancer
S Satthaporn et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex
A Castilleja et al.
JOURNAL OF IMMUNOLOGY (2002)
Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
JL Gong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)